Tremelimumab is under clinical development by AstraZeneca and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tremelimumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tremelimumab (Imjudo) human monoclonal antibody against CTLA-4. It is formulated as a solution for intravenous and subcutaneous route of administration. Imjudo is indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma and in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor.(EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Tremelimumab (CP-675206) is under development for the treatment of squamous and non-squamous non-small cell lung cancer, epithelial ovarian, cutaneous melanoma, fallopian tube or primary peritoneal carcinoma, urothelial bladder cancer, poorly differentiated thyroid carcinoma, anaplastic thyroid cancer, follicular thyroid cancer, medullary thyroid cancer and papillary thyroid cancer, renal cell carcinoma, metastatic breast cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast cancer, and HPV negative head and neck squamous cell carcinoma, oral cancer, oropharyngeal cancer, laryngeal cancer, metastatic adenocarcinoma of the pancreas and castrate resistant prostate cancer. The drug candidate is administered intravenously. It is fully human monoclonal antibody targeting human cytotoxic T lymphocyte–associated antigen 4 (CTLA-4, CD152). It was also under development for the treatment of HIV / AIDS, bladder cancer, colorectal cancer, prostate cancer, gastrointestinal tract cancer, metastatic melanoma, unresectable advanced solid tumors and pleural malignant mesothelioma.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Tremelimumab’s drug-specific PTSR and LoA scores, buy the report here.